Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Analysis of the RIMDAMAL trial - Authors' reply.

Foy BD, Rao S, Parikh S, Slater HC, Dabiré RK.

Lancet. 2019 Sep 21;394(10203):1006-1007. doi: 10.1016/S0140-6736(19)32139-7. No abstract available.

PMID:
31544742
2.

False-negative malaria rapid diagnostic test results and their impact on community-based malaria surveys in sub-Saharan Africa.

Watson OJ, Sumner KM, Janko M, Goel V, Winskill P, Slater HC, Ghani A, Meshnick SR, Parr JB.

BMJ Glob Health. 2019 Jul 29;4(4):e001582. doi: 10.1136/bmjgh-2019-001582. eCollection 2019.

3.

Author Correction: The temporal dynamics and infectiousness of subpatent Plasmodium falciparum infections in relation to parasite density.

Slater HC, Ross A, Felger I, Hofmann NE, Robinson L, Cook J, Gonçalves BP, Björkman A, Ouedraogo AL, Morris U, Msellem M, Koepfli C, Mueller I, Tadesse F, Gadisa E, Das S, Domingo G, Kapulu M, Midega J, Owusu-Agyei S, Nabet C, Piarroux R, Doumbo O, Doumbo SN, Koram K, Lucchi N, Udhayakumar V, Mosha J, Tiono A, Chandramohan D, Gosling R, Mwingira F, Sauerwein R, Paul R, Riley EM, White NJ, Nosten F, Imwong M, Bousema T, Drakeley C, Okell LC.

Nat Commun. 2019 Jun 11;10(1):2644. doi: 10.1038/s41467-019-10790-0.

4.

Impact of seasonal variations in Plasmodium falciparum malaria transmission on the surveillance of pfhrp2 gene deletions.

Watson OJ, Verity R, Ghani AC, Garske T, Cunningham J, Tshefu A, Mwandagalirwa MK, Meshnick SR, Parr JB, Slater HC.

Elife. 2019 May 2;8. pii: e40339. doi: 10.7554/eLife.40339.

5.

The temporal dynamics and infectiousness of subpatent Plasmodium falciparum infections in relation to parasite density.

Slater HC, Ross A, Felger I, Hofmann NE, Robinson L, Cook J, Gonçalves BP, Björkman A, Ouedraogo AL, Morris U, Msellem M, Koepfli C, Mueller I, Tadesse F, Gadisa E, Das S, Domingo G, Kapulu M, Midega J, Owusu-Agyei S, Nabet C, Piarroux R, Doumbo O, Doumbo SN, Koram K, Lucchi N, Udhayakumar V, Mosha J, Tiono A, Chandramohan D, Gosling R, Mwingira F, Sauerwein R, Paul R, Riley EM, White NJ, Nosten F, Imwong M, Bousema T, Drakeley C, Okell LC.

Nat Commun. 2019 Mar 29;10(1):1433. doi: 10.1038/s41467-019-09441-1. Erratum in: Nat Commun. 2019 Jun 11;10(1):2644.

6.

Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial.

Foy BD, Alout H, Seaman JA, Rao S, Magalhaes T, Wade M, Parikh S, Soma DD, Sagna AB, Fournet F, Slater HC, Bougma R, Drabo F, Diabaté A, Coulidiaty AGV, Rouamba N, Dabiré RK.

Lancet. 2019 Apr 13;393(10180):1517-1526. doi: 10.1016/S0140-6736(18)32321-3. Epub 2019 Mar 14.

7.

Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial.

Smit MR, Ochomo EO, Aljayyoussi G, Kwambai TK, Abong'o BO, Chen T, Bousema T, Slater HC, Waterhouse D, Bayoh NM, Gimnig JE, Samuels AM, Desai MR, Phillips-Howard PA, Kariuki SK, Wang D, Ward SA, Ter Kuile FO.

Lancet Infect Dis. 2018 Jun;18(6):615-626. doi: 10.1016/S1473-3099(18)30163-4. Epub 2018 Mar 27.

8.

The Relative Contribution of Symptomatic and Asymptomatic Plasmodium vivax and Plasmodium falciparum Infections to the Infectious Reservoir in a Low-Endemic Setting in Ethiopia.

Tadesse FG, Slater HC, Chali W, Teelen K, Lanke K, Belachew M, Menberu T, Shumie G, Shitaye G, Okell LC, Graumans W, van Gemert GJ, Kedir S, Tesfaye A, Belachew F, Abebe W, Mamo H, Sauerwein R, Balcha T, Aseffa A, Yewhalaw D, Gadisa E, Drakeley C, Bousema T.

Clin Infect Dis. 2018 Jun 1;66(12):1883-1891. doi: 10.1093/cid/cix1123.

9.

The US President's Malaria Initiative, Plasmodium falciparum transmission and mortality: A modelling study.

Winskill P, Slater HC, Griffin JT, Ghani AC, Walker PGT.

PLoS Med. 2017 Nov 21;14(11):e1002448. doi: 10.1371/journal.pmed.1002448. eCollection 2017 Nov.

10.

Model citizen - Authors' reply.

Brady OJ, Slater HC, Pemberton-Ross P, Wenger E, Maude RJ, Ghani AC, Penny MA, Gerardin J, White LJ, Chitnis N, Aguas R, Hay SI, Smith DL, Stuckey EM, Okiro EA, Smith TA, Okell LC.

Lancet Glob Health. 2017 Oct;5(10):e974. doi: 10.1016/S2214-109X(17)30338-8. No abstract available.

11.

Modelling the drivers of the spread of Plasmodium falciparum hrp2 gene deletions in sub-Saharan Africa.

Watson OJ, Slater HC, Verity R, Parr JB, Mwandagalirwa MK, Tshefu A, Meshnick SR, Ghani AC.

Elife. 2017 Aug 24;6. pii: e25008. doi: 10.7554/eLife.25008.

12.

Role of mass drug administration in elimination of Plasmodium falciparum malaria: a consensus modelling study.

Brady OJ, Slater HC, Pemberton-Ross P, Wenger E, Maude RJ, Ghani AC, Penny MA, Gerardin J, White LJ, Chitnis N, Aguas R, Hay SI, Smith DL, Stuckey EM, Okiro EA, Smith TA, Okell LC.

Lancet Glob Health. 2017 Jul;5(7):e680-e687. doi: 10.1016/S2214-109X(17)30220-6. Epub 2017 May 26.

13.

A novel model fitted to multiple life stages of malaria for assessing efficacy of transmission-blocking interventions.

Sherrard-Smith E, Churcher TS, Upton LM, Sala KA, Zakutansky SE, Slater HC, Blagborough AM, Betancourt M.

Malar J. 2017 Apr 4;16(1):137. doi: 10.1186/s12936-017-1782-3.

14.

Pfhrp2-Deleted Plasmodium falciparum Parasites in the Democratic Republic of the Congo: A National Cross-sectional Survey.

Parr JB, Verity R, Doctor SM, Janko M, Carey-Ewend K, Turman BJ, Keeler C, Slater HC, Whitesell AN, Mwandagalirwa K, Ghani AC, Likwela JL, Tshefu AK, Emch M, Juliano JJ, Meshnick SR.

J Infect Dis. 2017 Jul 1;216(1):36-44. doi: 10.1093/infdis/jiw538.

15.

Oral, ultra-long-lasting drug delivery: Application toward malaria elimination goals.

Bellinger AM, Jafari M, Grant TM, Zhang S, Slater HC, Wenger EA, Mo S, Lee YL, Mazdiyasni H, Kogan L, Barman R, Cleveland C, Booth L, Bensel T, Minahan D, Hurowitz HM, Tai T, Daily J, Nikolic B, Wood L, Eckhoff PA, Langer R, Traverso G.

Sci Transl Med. 2016 Nov 16;8(365):365ra157.

16.

Mathematical Modelling to Guide Drug Development for Malaria Elimination.

Slater HC, Okell LC, Ghani AC.

Trends Parasitol. 2017 Mar;33(3):175-184. doi: 10.1016/j.pt.2016.09.004. Epub 2016 Oct 7. Review.

17.

Model-Based Geostatistical Mapping of the Prevalence of Onchocerca volvulus in West Africa.

O'Hanlon SJ, Slater HC, Cheke RA, Boatin BA, Coffeng LE, Pion SD, Boussinesq M, Zouré HG, Stolk WA, Basáñez MG.

PLoS Negl Trop Dis. 2016 Jan 15;10(1):e0004328. doi: 10.1371/journal.pntd.0004328. eCollection 2016 Jan.

18.

Assessing the potential impact of artemisinin and partner drug resistance in sub-Saharan Africa.

Slater HC, Griffin JT, Ghani AC, Okell LC.

Malar J. 2016 Jan 6;15:10. doi: 10.1186/s12936-015-1075-7.

19.

Assessing the impact of next-generation rapid diagnostic tests on Plasmodium falciparum malaria elimination strategies.

Slater HC, Ross A, Ouédraogo AL, White LJ, Nguon C, Walker PG, Ngor P, Aguas R, Silal SP, Dondorp AM, La Barre P, Burton R, Sauerwein RW, Drakeley C, Smith TA, Bousema T, Ghani AC.

Nature. 2015 Dec 3;528(7580):S94-101. doi: 10.1038/nature16040.

20.

Efficacy and safety of the mosquitocidal drug ivermectin to prevent malaria transmission after treatment: a double-blind, randomized, clinical trial.

Ouédraogo AL, Bastiaens GJ, Tiono AB, Guelbéogo WM, Kobylinski KC, Ouédraogo A, Barry A, Bougouma EC, Nebie I, Ouattara MS, Lanke KH, Fleckenstein L, Sauerwein RW, Slater HC, Churcher TS, Sirima SB, Drakeley C, Bousema T.

Clin Infect Dis. 2015 Feb 1;60(3):357-65. doi: 10.1093/cid/ciu797. Epub 2014 Nov 19. Erratum in: Clin Infect Dis. 2016 Sep 1;63(5):715.

PMID:
25414262
21.

The potential impact of adding ivermectin to a mass treatment intervention to reduce malaria transmission: a modelling study.

Slater HC, Walker PG, Bousema T, Okell LC, Ghani AC.

J Infect Dis. 2014 Dec 15;210(12):1972-80. doi: 10.1093/infdis/jiu351. Epub 2014 Jun 20.

PMID:
24951826
22.

Modelling co-infection with malaria and lymphatic filariasis.

Slater HC, Gambhir M, Parham PE, Michael E.

PLoS Comput Biol. 2013;9(6):e1003096. doi: 10.1371/journal.pcbi.1003096. Epub 2013 Jun 13.

23.

Sebaceous carcinoma of the eyelid.

Dixon RS, Mikhail GR, Slater HC.

J Am Acad Dermatol. 1980 Sep;3(3):241-3.

PMID:
7451690

Supplemental Content

Loading ...
Support Center